## Distinguishing Malignant Hyperthermia Susceptibility from Central Core Disease ### Genetic Overlap and Clinical Distinction Both malignant hyperthermia susceptibility (MHS) and central core disease (CCD) can result from mutations in the **RYR1 gene** (ryanodine receptor). Critically, both conditions share **muscle weakness/hypotonia** as a feature — CCD is a congenital myopathy with weakness, but MHS patients may also have subclinical myopathy with mild proximal weakness. Therefore, muscle weakness alone does **not** reliably distinguish MHS from CCD in a RYR1-mutation carrier. ### Key Discriminating Feature **Key Point:** An **elevated baseline serum creatine kinase (CK) in the absence of anesthetic exposure** is the best laboratory finding that distinguishes CCD from isolated MHS. In CCD, constitutive calcium dysregulation causes ongoing sarcomeric damage and chronic muscle fiber injury, resulting in persistently elevated CK even at rest. In isolated MHS, baseline CK is typically **normal** (or only transiently elevated after exercise or a triggering event), because the RYR1 channel dysfunction is latent and only activated by triggering agents. ### Comparison Table | Feature | Malignant Hyperthermia Susceptibility | Central Core Disease | |---------|----------------------------------------|----------------------| | **Baseline serum CK** | Normal (or mildly elevated post-exercise) | Mildly to moderately elevated at rest | | **Baseline muscle strength** | Normal (or subclinical weakness) | Proximal weakness, hypotonia | | **Muscle biopsy** | Normal or nonspecific | Central cores (devoid of oxidative enzymes) | | **CHCT result** | Positive | Also positive (not distinguishing) | | **Anesthetic trigger** | Required for crisis | Crisis can occur with any anesthetic | | **Inheritance** | Autosomal dominant (RYR1 or CACNA1S) | Autosomal dominant (RYR1 most common) | ### Why the Other Options Are Incorrect - **Option A (Muscle weakness/hypotonia at rest):** While CCD classically presents with congenital myopathy, MHS patients with RYR1 mutations can also have subclinical proximal weakness. This finding is suggestive but not the *best* distinguishing laboratory/clinical marker in a comparison question. - **Option B (Triggered exclusively by succinylcholine and volatile anesthetics):** This is true for MHS, but the question asks what distinguishes the *patient's risk* — this describes MHS physiology, not a finding that differentiates the two conditions in a clinical/lab workup. - **Option D (Positive CHCT):** Both MHS and CCD patients show a **positive caffeine-halothane contracture test**, making this finding non-discriminatory between the two conditions. ### Pathophysiologic Basis In CCD, the RYR1 mutation causes **constitutive (baseline) calcium leak** from the sarcoplasmic reticulum, leading to chronic mitochondrial dysfunction, structural muscle damage (central cores on histology), and ongoing CK release. In MHS, the RYR1 channel is abnormally sensitive to triggering agents but remains functionally quiescent at baseline — hence normal resting CK. ### Clinical Pearl **Clinical Pearl:** A persistently elevated baseline CK in a RYR1-mutation carrier without recent anesthetic exposure or strenuous exercise should prompt evaluation for CCD (muscle biopsy for central cores). This finding has direct perioperative implications: CCD patients require dantrolene prophylaxis and avoidance of all triggering agents, whereas isolated MHS patients need only to avoid succinylcholine and volatile anesthetics. **High-Yield:** Baseline CK elevation at rest = CCD; Normal baseline CK = isolated MHS. Both will have a positive CHCT. [cite: Miller's Anesthesia 9e, Ch 34; Rosenberg et al., Malignant Hyperthermia, Orphanet J Rare Dis 2015; Jungbluth H, Central Core Disease, Orphanet J Rare Dis 2007]
Sign up free to access AI-powered MCQ practice with detailed explanations and adaptive learning.